Immunoclin Corp (IMCLE)

0.50 10.00
OTC : Health Care
Prev Close 5.00
Open 5.50
Day Low/High 5.50 / 5.50
52 Wk Low/High 2.05 / 5.60
Volume 100.00
Exchange OTC
Shares Outstanding 28.83M
Market Cap 158.57M
EPS -1.20
P/E Ratio N/A
Div & Yield N.A. (N.A)

ImClone Regains Compliance With Nasdaq National Market

The company's stock symbol will revert to IMCL on July 10.

ImClone Partner Seeks European Approval for Erbitux

Merck KGaA files for clearance with European Union and Swiss regulators.

ImClone's Loss Widens, Revenue Grows

The biotech company's stock is higher following the report, which had been delayed.

ImClone Reports Delayed Results

The company posts mixed results for the fourth quarter and full year 2002.

Martha's Trial Set for January

The former CEO of Martha Stewart Living is facing fraud and obstruction of justice charges.

Fast Track Doesn't Equal Sure Thing

Biotech firms use fast-track approval to get stocks moving up.

Insider Trading Is Easy -- So Is Getting Caught

The exchanges have surveillance teams that track the slightest irregularities.

It's Hard to Hang a Number on ImClone

Even assuming Erbitux is approved, figuring out a valuation is more art than science.

Edgy Money-Runners Chase Big Quarter-End Score

They're making risky bets now, hoping they can save face. Has your stock become a lottery ticket?

Sam Waksal Gets Seven Years for ImClone Scandal

The biotech's ex-CEO is sentenced after pleading guilty to insider trading and obstruction of justice.

Oxigene Soars as Compound Gets Added Study

The biotech company's shares rise 80%, and volume is extremely heavy.

Wondering When Biotech's Happy Hour Will End

Fundamental reasons support a continued rally, but investors may be inebriated with the froth.

ImClone Jumps on Plan to Refile Erbitux

The company will submit a biologics license application later this year for the cancer drug.

Not Too Troubled by the Biotech Bubble

The FDA's willingness to approve niche drugs is one reason why there's still room for more upside.

Stewart Board Stands Behind Maligned Martha

Director Arthur Martinez rejects rumors that Stewart will step down as a possible indictment looms.

Investors Flee as Probe Hits Martha

The U.S. Attorney launches a criminal investigation, and an SEC complaint is expected.

Onyx Gives Investors a Peep Show

The biotech reveals some tantalizing data on its new cancer drug BAY 43-9006.

Stocks Hit Resistance After Soaring Most of Day

The S&P 500's close above 965 may be the most telling technical indicator on an otherwise disappointing day.

Rally Loses Steam

The averages end mixed after hitting new highs for the year earlier in the day.

ASCO Has Biotechs Riding High

Good news out of the cancer research meeting gives a boost to several names in the group.

Erbitux's Numbers Look as Good as in 2001

Results from the European study show similar survival benefits as earlier data.

Abgenix's Drug May Not Match Wall Street's High Hopes

ABX-EGF works on tumors, but the Street might find the efficacy rates disappointing.

Hope for Erbitux Again Lifts ImClone

The biotech company's stock is higher following a positive report ahead of the ASCO meeting.

Allos Hopes to Find a Friendly FDA

The company plans to submit an application for a new cancer treatment, but the data sample is small.

ImClone Jumps, and the Biotech Sector Surges

Several stocks in the group are posting hefty gains in late-morning trading.

Markets Applaud Tax News

The major averages end around 1% higher, as Congress prepares to enact tax relief.

What to Put on Your ASCO Shopping List

More than 2,000 abstracts will be released in one day -- here's what to look for.

Revisiting Erbitux's European Data

The cancer drug performed much better in a European clinical trial than preliminary results indicated.